In short: Hair cloning is a research goal, not an ordinary FUE or FUT procedure. Scientists aim to expand hair-inductive cells and build additional follicles, but current models reproduce only parts of a functioning human follicle. The inspected sources do not establish routine, clinically validated hair cloning in the UK.
Hair cloning is not a routine clinical alternative to FUE or FUT. Researchers aim to expand hair-inductive cells and use them to generate additional working follicles, but reviews of tissue engineering and functional follicle regeneration describe major biological and manufacturing barriers before that goal can become a validated human treatment.
What would hair cloning involve?
The name suggests copying a complete hair, but the research problem is more complex. A review of tissue-engineering strategies for human hair follicle regeneration describes the central idea as taking relevant follicular cells, expanding them outside the body and assembling them so that they can generate functional follicles after transplantation.
Researchers often focus on interactions between epithelial cells and dermal cells. The same review explains that these cell populations communicate during follicle development, and that cultured dermal cells can lose the ability to induce a new follicle. Producing more cells is therefore not enough. The expanded cells must retain or regain the biological signals and organisation needed to form a working follicle.
A clinically useful follicle would need to do more than produce a strand in a dish or on an animal. The tissue-engineering review says regenerated follicles would need appropriate structure, orientation, density, hair type and pigmentation, integration with the surrounding skin, and the ability to respond to normal physiological signals. Hair cycling and durability would also need to be shown in people.
The tissue-engineering literature also discusses follicle multiplication and bioengineered follicles, while other research uses follicular organoids as models. These related terms should not be treated as proof of a finished clinical cloning procedure.
How far has the research progressed?
Laboratory and animal studies have produced partial follicle-like structures and useful models, but that is not the same as restoring durable human scalp hair. A review of functional hair follicle regeneration found that available strategies reproduced only part of a follicle’s structure and function and remained far from clinical translation at publication.
Several barriers recur across the research. The functional-regeneration review describes loss of hair-inductive ability during cell culture, inefficient reprogramming, incomplete organisation between epithelial and mesenchymal cells, and difficulty recreating the follicle’s surrounding biological environment. It also identifies uncertainty about production yield, normal function and durability.
Results in mice need careful interpretation. The tissue-engineering review explains that animal or xenograft models can involve mouse-cell contributions and do not establish that cultured patient cells will create normal, lasting follicles in a human scalp. A follicle-like structure, a hair shaft or a short observation period answers only part of the clinical question.
A 2024 review of hair-follicle development and regeneration still describes regenerative strategies as emerging. It calls for more clinical validation and identifies continuing limitations and uncertainty. That review reports the direction of research, not evidence that a cloning treatment is ready for routine use.
How does cloning differ from FUE, FUT and stem-cell treatments?
Ordinary transplantation redistributes existing follicles. The NHS hair transplant guide says FUT removes a strip of hair-bearing skin that is divided into grafts, while FUE removes individual grafts one by one. The grafts are then placed into small cuts in the thinning area. The donor supply is not multiplied.
Hair cloning aims to create additional functional follicles from expanded cells. The tissue-engineering review presents this as a possible way to move beyond the donor-supply constraint, but also states that human follicle formation from cultured patient cells had not been successfully achieved and clinical tissue-engineering applications were absent at the time of publication.
"Stem cell hair treatment" is a broader and often ambiguous label. A review of cell therapy for androgenetic alopecia separates living-cell treatments from conditioned media, cellular extracts and extracellular vesicles. Those approaches may try to influence existing follicles. They do not demonstrate that new, transplantable follicles have been cloned.
The NHS defines transplantation by the movement of donor grafts, while the cell-therapy review separates cells, secretions and extracts. Hair cloning would need to show that expanded cells produced additional, functional follicles suitable for human implantation.
When might hair cloning become available?
The reviewed evidence does not support a dependable date. Progress depends on solving linked problems in cell expansion, follicle organisation, manufacturing consistency, implantation, orientation, cycling, appearance and long-term safety. The 2020 tissue-engineering review and 2021 functional-regeneration review describe these as unresolved translational barriers rather than small refinements to an otherwise finished procedure.
The MHRA guidance on advanced therapy medicinal products says advanced therapies must undergo clinical trials, and products placed on the UK market require marketing authorisation. The MHRA assesses quality, safety and efficacy. Restricted routes exist for some unlicensed products, so the presence of an experimental route should not be presented as general marketing approval.
A company announcement, patent, laboratory image or trial registration can show activity, but it cannot establish clinical effectiveness or product-specific authorisation under the MHRA framework. Claims that cloning is "coming soon" need a named product, published human results, regulatory details and a clearly defined treatment protocol before they can be assessed.
Risks and what can go wrong
The first risk is paying for something that does not match the name. The NHS transplant description, cell-therapy taxonomy and cloning research definition describe different procedures. Ask whether the provider creates additional follicles and what published human evidence demonstrates that result.
True bioengineered-follicle treatment would also present unresolved biological risks. Reviews identify uncertainty about whether cultured cells retain the required function, whether engineered structures integrate and cycle normally, and whether results last. The functional-regeneration review says evidence about normal function and durability remains limited, while the 2024 status review calls for further clinical validation.
The MHRA assesses the quality, safety and efficacy of advanced therapies before marketing authorisation. Without product-specific evidence, a reader cannot assume that cultured follicle cells were processed consistently, that each manufactured dose is reproducible or that long-term risks have been characterised.
If a marketed package includes FUE or FUT, the standard surgical risks remain. The NHS lists bleeding, infection, allergic reaction to anaesthetic, noticeable scarring, failure of the transplant to take and continued thinning around the grafted area. FUT leaves a linear scar, while FUE leaves many small scars.
For treatment outside the UK, distance can make examination and follow-up harder if a complication appears after the journey home. The NHS guidance on going abroad for treatment advises checking complication plans, aftercare, insurance and recovery time before travel. Any decision about when to travel must come from the treating clinic after assessment and review.
Questions to ask the clinic
Use the same questions for a clinic, company or trial recruiter:
- Are you offering ordinary FUE or FUT, a cell-based treatment, or the creation of additional follicles from expanded cells?
- What is the exact product or procedure name, and which parts are experimental?
- Which peer-reviewed human study tested this exact method and showed new functional follicles rather than changes in existing hair?
- How many people received the finished procedure, and how long were follicle cycling, appearance and safety followed?
- What is the product’s UK regulatory status, and can you provide the relevant MHRA marketing-authorisation or trial details?
- Who performs the procedure and takes clinical responsibility for complications or poor growth?
- If FUE or FUT is included, how is donor hair assessed and how are surgical risks explained separately from the experimental element?
- How will in-person follow-up and urgent care work after I return to the UK?
Talk it through
If you are comparing research claims with a conventional hair transplant, GetHair can arrange a free consultation with a partner clinic in Turkey. The partner clinic assesses your scalp and donor hair, explains the procedure it performs and takes responsibility for clinical decisions and surgery.
Sources
- NHS: Hair transplant
- NHS: Going abroad for treatment
- MHRA: Advanced therapy medicinal products regulation and licensing in the UK
- Tissue engineering strategies for human hair follicle regeneration
- Functional hair follicle regeneration: an updated review
- Status of research on development and regeneration of hair follicles
- Cell therapy for androgenetic alopecia: elixir or trick?